The MDM2 oncoprotein is overexpressed in rhabdomyosarcoma cell lines and stabilizes wild-type p53 protein

American Journal of Pathology

Volumn 149, Issue 1, 1996, Pages 143-151

  Keleti, Julia ^a   Quezado, Martha M ^a   Abaza, Mona M ^a   Raffeld, Mark ^a   Tsokos, Maria ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MESSENGER RNA; ONCOPROTEIN; PROTEIN P53;

ARTICLE; CHILDHOOD CANCER; CONTROLLED STUDY; GENE AMPLIFICATION; GENE EXPRESSION; GENE MUTATION; HALF LIFE TIME; HUMAN; HUMAN CELL; ONCOGENE; PRIORITY JOURNAL; RHABDOMYOSARCOMA; SARCOMA CELL; TUMOR SUPPRESSOR GENE;

BLOTTING, NORTHERN; BLOTTING, SOUTHERN; CELL NUCLEUS; GENE AMPLIFICATION; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOHISTOCHEMISTRY; POLYMERASE CHAIN REACTION; POLYMORPHISM, SINGLE-STRANDED CONFORMATIONAL; PROTO-ONCOGENE PROTEINS; RHABDOMYOSARCOMA; RNA, MESSENGER; TUMOR CELLS, CULTURED; TUMOR SUPPRESSOR PROTEIN P53;

EID: 0029901963     PISSN: 00029440     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (58)

1. Levine AJ, Momand J, Finlay CA: The p53 tumour suppressor gene. Nature 1991, 351:453-456
2. el-Deiry WS, Tokino T, Velculescu VE, Levy DB, Parsons R, Trent JM, Lin D, Mercer WE, Kinzler KW, Vogelstein B: WAF1, a potential mediator of p53 tumor suppression. Cell 1993, 75:817-825
3. Nigro JM, Baker SJ, Preisinger AC, Jessup JM, Hostetter R, Cleary K, Bigner SH, Davidson N, Baylin S, Devilee P: Mutations in the p53 gene occur in diverse human tumour types. Nature 1989, 342:705-708
4. Yew PR, Berk AJ: Inhibition of p53 transactivation required for transformation by adenovirus early 1B protein. Nature 1992, 357:82-85
5. Mietz JA, Unger T, Huibregtse JM, Howley PM: The transcriptional transactivation function of wild-type p53 is inhibited by SV40 large T-antigen and by HPV-16 E6 oncoprotein. EMBO J 1992, 11:5013-5020
6. Momand J, Zambetti GP, Olson DC, George D, Levine AJ: The mdm2 oncogene product forms a complex with the p53 protein and inhibits p53-mediated transactivation. Cell 1992, 69:1237-1245
7. Oliner JD, Pietenpol JA, Thiagalingam S, Gyuris J, Kinzler KW, Vogelstein B: Oncoprotein MDM2 conceals the activation domain of tumour suppressor p53. Nature 1993, 362:857-860
8. Haines DS, Landers JE, Engle LJ, George DL: Physical and functional interaction between wild-type p53 and mdm2 proteins. Mol Cell Biol 1994, 14:1171-1178
9. Barak Y, Juven T, Haffner R, Oren M: mdm2 expression is induced by wild type p53 activity. EMBO J 1993, 12:461-468
10. Fakharzadeh SS, Trusko SP, George DL: Tumorigenic potential associated with enhanced expression of a gene that is amplified in a mouse tumor cell line. EMBO J 1991, 10:1565-1569
11. Perry ME, Piette J, Zawadzki JA, Harvey D, Levine AJ: The mdm-2 gene is induced in response to UV light in a p53-dependent manner. Proc Natl Acad Sci USA 1993, 90:11623-11627
12. Zauberman A, Barak Y, Ragimov N, Levy N, Oren M: Sequence-specific DNA binding by p53: identification of target sites and lack of binding to p53-MDM2 complexes. EMBO J 1993, 12:2799-2808
13. Wu X, Bayle JH, Olson D, Levine AJ: The p53-MDM-2 autoregulatory feedback loop Genes Dev 1993, 7:1126-1132
14. Leach FS, Tokino T, Meltzer P, Burrell M, Oliner JD, Smith S, Hill DE, Sidransky D, Kinzler KW, Vogelstein B: p53 mutation and MDM2 amplification in human soft tissue sarcomas. Cancer Res 1993, 53:2231-2234
15. Oliner JD, Kinzler KW, Meltzer PS, George DL, Vogelstein B: Amplification of a gene encoding a p53-associated protein in human sarcomas. Nature 1992, 358:80-83
16. Reifenberger G, Liu L, Ichimura K, Schmidt EE, Collins VP: Amplification and overexpression of the MDM2 gene in a subset of human malignant gliomas without p53 mutations. Cancer Res 1993, 53:2736-2739
17. Bueso-Ramos CE, Yang Y, deLeon E, McCown P, Stass SA, Albitar M: The human MDM-2 oncogene is overexpressed in leukemias. Blood 1993, 82:2617-2623
18. Lianes P, Orlow I, Zhang ZF, Oliva MR, Sarkis AS, Reuter VE, Cordon-Cardo C: Altered patterns of MDM2 and TP53 expression in human bladder cancer. J Natl Cancer Inst 1994, 86:1325-1330
19. Habuchi T, Kinoshita H, Yamada H, Kakehi Y, Ogawa O, Wu WJ, Takahashi R, Sugiyama T, Yoshida O: Oncogene amplification in urothelial cancers with p53 gene mutation or MDM2 amplification. J Natl Cancer Inst 1994, 86:1331-1335
20. Waber PG, Chen J, Nisen PD: Infrequency of MDM2 gene amplification in pediatric solid tumors and lack of association with p53 mutations in adult squamous cell carcinomas. Cancer Res 1993, 53:6028-6030
21. Bardeesy N, Falkoff D, Petruzzi MJ, Nowak N, Zabel B, Adam M, Aguiar MC, Grundy P, Shows T, Pelletier J: Anaplastic Wilms' tumour, a subtype displaying poor prognosis, harbours p53 gene mutations. Nat Genet 1994, 7:91-97
22. Ladanyi M, Cha C, Lewis R, Jhanwar SC, Huvos AG, Healey JH: MDM2 gene amplification in metastatic osteosarcoma. Cancer Res 1993, 53:16-18
23. Kovar H, Auinger A, Jug G, Aryee D, Zoubek A, Salzer-Kuntschik M, Gadner H: Narrow spectrum of infrequent p53 mutations and absence of MDM2 amplification in Ewing tumours. Oncogene 1993, 8:2683-2690
24. Adesina AM, Nalbantoglu J, Cavenee WK: p53 gene mutation and mdm2 gene amplification are uncommon in medulloblastoma. Cancer Res 1994, 54:5649-5651
25. Ladanyi M, Lewis R, Jhanwar SC, Gerald W, Huvos AG, Healey JH: MDM2 and CDK4 gene amplification in Ewing's sarcoma. J Pathol 1995, 175:211-217
26. Sheikh MS, Shao ZM, Hussein A, Fontana JA: The p53-binding protein MDM2 gene is differentially expressed in human breast carcinoma. Cancer Res 1993, 53:3226-3228
27. Landers JE, Haines DS, Strauss JF, George DL: Enhanced translation: a novel mechanism of mdm2 oncogene overexpression identified in human tumor cells. Oncogene 1994, 9:2745-2750
28. Florenes VA, Maelandsmo GM, Forus A, Andreassen A, Myklebost O, Fodstad O: MDM2 gene amplification and transcript levels in human sarcomas: relationship to TP53 gene status. J Natl Cancer Inst 1994, 86:1297-1302
29. Felix CA, Kappel CC, Mitsudomi T, Nau MM, Tsokos M, Crouch GD, Nisen PD, Winick NJ, Helman LJ: Frequency and diversity of p53 mutations in childhood rhabdomyosarcoma. Cancer Res 1992, 52:2243-2247
30. Mulligan LM, Matlashewski GJ, Scrable HJ, Cavenee WK: Mechanisms of p53 loss in human sarcomas. Proc Natl Acad Sci USA 1990, 87:5863-5867
31. Li FP, Fraumeni JFJ, Mulvihill JJ, Blattner WA, Dreyfus MG, Tucker MA, Miller RW: A cancer family syndrome in twenty-four kindreds. Cancer Res 1988, 48:5358-5362
32. Malkin D, Li FP, Strong LC, Fraumeni JFJ, Nelson CE, Kim DH, Kassel J, Gryka MA, Bischoff FZ, Tainsky MA: Germ line p53 mutations in a familial syndrome of breast cancer, sarcomas, and other neoplasms. Science 1990, 250:1233-1238
33. Santibanez-Koref MF, Birch JM, Hartley AL, Jones PH, Craft AW, Eden T, Crowther D, Kelsey AM, Harris M: p53 germline mutations in Li-Fraumeni syndrome. Lancet 1991, 338:1490-1491
34. McAllister RM, Melnyk J, Finkelstein JZ, Adams ECJ, Gardner MB: Cultivation in vitro of cells derived from a human rhabdomyosarcoma. Cancer 1969, 24:520-526
35. Whang-Peng J, Knutsen T, Theil K, Horowitz ME, Triche T: Cytogenetic studies in subgroups of rhabdomyosarcoma. Genes Chromosomes & Cancer 1992, 5:299-310
36. Douglass EC, Valentine M, Etcubanas E, Parham D, Webber BL, Houghton PJ, Houghton JA, Green AA: A specific chromosomal abnormality in rhabdomyosarcoma [published erratum appears in Cytogenet Cell Genet 1988, 47(4): following 232]. Cytogenet Cell Genet 1987, 45:148-155
37. Davis LG, Dibner MD, Battey JF: Basic Methods in Molecular Biology. New York, Elsevier, 1992
38. Chirgwin JM, Przybyla AE, MacDonald RJ, Rutter WJ: Isolation of biologically active ribonucleic acid from sources enriched in ribonuclease. Biochemistry 1979, 18:5294-5299
39. Lipford EH, Smith HR, Pittaluga S, Jaffe ES, Steinberg AD, Cossman J: Clonality of angioimmunoblastic lymphadenopathy and implications for its evolution to malignant lymphoma. J Clin Invest 1987, 79:637-642
40. Tso JY, Sun XH, Kao TH, Reece KS, Wu R: Isolation and characterization of rat and human glyceraldehyde-3-phosphate dehydrogenase cDNAs: genomic complexity and molecular evolution of the gene. Nucleic Acids Res 1985, 13:2485-2502
41. Zakut-Houri R, Bienz-Tadmor B, Givol D, Oren M: Human p53 cellular tumor antigen: cDNA sequence and expression in COS cells. EMBO J 1985, 4:1251-1255
42. Orita M, Suzuki Y, Sekiya T, Hayashi K: Rapid and sensitive detection of point mutations and DNA polymorphisms using the polymerase chain reaction. Genomics 1989, 5:874-879
43. Gaidano G, Ballerini P, Gong JZ, Inghirami G, Neri A, Newcomb EW, Magrath IT, Knowles DM, Dalla-Favera R: p53 mutations in human lymphoid malignancies: association with Burkitt lymphoma and chronic lymphocytic leukemia. Proc Natl Acad Sci USA 1991, 88: 5413-5417
44. Jaffe ES, Raffeld M: Identification of cell in tissue section. Current Protocols in Immunology. Edited by JE Coligan, AM Kruisbeck, DH Margulies, EM Shevach, W Strober. New York, Wiley, 1991, p 581
45. Oren M, Maltzman W, Levine AJ: Post-translational regulation of the 54K cellular tumor antigen in normal and transformed cells. Mol Cell Biol 1981, 1:101-110
46. Reich NC, Oren M, Levine AJ: Two distinct mechanisms regulate the levels of a cellular tumor antigen, p53. Mol Cell Biol 1983, 3:2143-2150
47. Rogel A, Popliker M, Webb CG, Oren M: p53 cellular tumor antigen: analysis of mRNA levels in normal adult tissues, embryos, and tumors. Mol Cell Biol 1985, 5:2851-2855
48. Rovinski B, Benchimol S: Immortalization of rat embryo fibroblasts by the cellular p53 oncogene. Oncogene 1988, 2:445-452
49. Reihsaus E, Kohler M, Kraiss S, Oren M, Montenarh M: Regulation of the level of the oncoprotein p53 in non-transformed and transformed cells. Oncogene 1990, 5:137-145
50. Olson DC, Marechal V, Momand J, Chen J, Romocki C, Levine AJ: Identification and characterization of multiple MDM-2 proteins and MDM-2-p53 protein complexes. Oncogene 1993, 8:2353-2360
51. Fintay CA: The mdm-2 oncogene can overcome wildtype p53 suppression of transformed cell growth. Mol Cell Biol 1993, 13:301-306
52. Huang YQ, Raphael B, Buchbinder A, Li JJ, Zhang WG, Friedman-Kien AE: Rearrangement and expression of mdm2 oncogene in chronic lymphocytic leukemia. Am J Hematol 1994, 47:139-141
53. Chang F, Syrjanen S, Tervahauta A, Syrjanen K: Tumourigenesis associated with the p53 tumour suppressor gene. Br J Cancer 1993, 68:653-661
54. Sarnow P, Ho YS, Williams J, Levine AJ: Adenovirus E1b-58 kDa tumor antigen and SV40 large tumor antigen are physically associated with the same 54 kDa cellular protein in transformed cells. Cell 1982, 28:387-394
55. Lin J, Chen J, Elenbaas B, Levine AJ: Several hydrophobic amino acids in the p53 amino-terminal domain are required for transcriptional activation, binding to mdm-2 and the adenovirus 5 E1B 55-kD protein. Genes Dev 1994, 8:1235-1246
56. Maestro R, Gloghini A, Doglioni C, Gasparotto D, Vukosavljevic T, De Re V, Laurino L, Carbone A, Boiocchi M: MDM2 overexpression does not account for stabilization of wild-type p53 protein in non-Hodgkin's lymphomas. Blood 1995, 85:3239-3246
57. Riou G, Barrois M, Prost S, Terrier MJ, Theodore C, Levine AJ: The p53 and mdm-2 genes in human testicular germ-cell tumors. Mol Carcinogen 1995, 12: 124-131
58. Cordon-Cardo C, Latres E, Drobnjak M, Oliva MR, Pollack D, Woodruff JM, Marechal V, Chen J, Brennan MF, Levine AJ: Molecular abnormalities of mdm2 and p53 genes in adult soft tissue sarcomas. Cancer Res 1994, 54:794-799